---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-034523"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T09:09:01.231608+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Armata Pharma Q4 net loss $124.3M on $105.8M non-cash fair value loss; going concern noted

## Summary
- Q4 2025 grant revenue $1.1M vs $1.2M YoY; R&D expenses $6.1M vs $8.5M YoY.
- Net loss $124.3M ($3.42/sh) vs net income $2.6M ($0.07/sh) in Q4 2024; includes $105.8M non-cash fair value loss on convertible loan.
- Recognized $5.4M impairment expense on vacated Marina del Rey office lease.
- Cash & equivalents $14.1M as of Dec 31 2025; amended debt agreements extending maturities to June 2027.
- Audited 2025 financials include going concern qualification; ~36.6M shares outstanding as of Mar 18 2026.

## SEC filing metadata
- accession: 0001104659-26-034523
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926034523/0001104659-26-034523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926034523/armp-20260325x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-034523
- JSON: https://secwatch.observer/filing/0001104659-26-034523.json
- Plain text: https://secwatch.observer/filing/0001104659-26-034523.txt

## Key facts
- Earnings Releases
  Armata Pharmaceuticals, Inc. reported the three months and full fiscal year ended December 31, 2025 results: net income $124.3 million, EPS $(3.42) per share.
  - Period: the three months and full fiscal year ended December 31, 2025
  - Net income: $124.3 million
  - EPS: $(3.42) per share
  - Result: reported results
  source text: Armata Pharmaceuticals, Inc. announced its financial results for the three months and full fiscal year ended December 31, 2025, in the press release furnished hereto as Exhibit 99.1.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465926034523/0001104659-26-034523-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.